Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-29

Study Completion Date

2020-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NVAMD Satellite Study

NCT02251366

Neovascular Age Related Macular Degeneration

COMPLETED NA

Recurrent Neovascular Age-related Macular Degeneration After Therapy Suspension

NCT04659512

Age-related Macular Degeneration

COMPLETED

Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736

Macular Degeneration Choroidal Neovascularization

COMPLETED PHASE2/PHASE3

Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration

NCT05038371

Wet Macular Degeneration

TERMINATED

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532

Age-Related Macular Degeneration

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-vascular endothelial growth factor (anti-VEGF) treatment, thereby providing guidance as to when it is reasonable to treat with anti-VEGF and when it is necessary to displace the hemorrhage in addition to treating with anti-VEGF.

This is a prospective study that will enroll 98 patients with subretinal hemorrhage in the fovea \[also known as subfoveal hemorrhage (SFH)\] secondary to neovascular AMD at the Wilmer Eye Institute, Johns Hopkins Hospital (Downtown campus and all other Eye Care Network clinics). The primary endpoint is at month 12 and the secondary endpoint is at month 24. The duration of the study is 24 months.

Study visits will include a baseline visit, then monthly visits for 12 months, followed by standard care treatment visits in the second year until month 24. The patients will be stratified into two groups based on standard of care management: 1. Patients receiving intravitreal (IVT) anti-VEGF injections; 2. Patients undergoing SFH displacement followed by IVT anti-VEGF injections. Patients will receive monthly anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24; or SFH displacement (at investigators' discretion) followed by monthly IVT anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Submacular Hemorrhage Wet Macular Degeneration Neovascular Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anti-VEGF injection only

Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24

Anti-VEGF

Intervention Type DRUG

Standard of care treatment with anti-VEGF only

Hemorrhage displacement + Anti-VEGF

Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24

Hemorrhage displacement + Anti-VEGF

Intervention Type OTHER

Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti-VEGF

Standard of care treatment with anti-VEGF only

Intervention Type DRUG

Hemorrhage displacement + Anti-VEGF

Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent and authorization of use and disclosure of protected health information
* Age 50 years or older
* Presence of subretinal hemorrhage (SRH) involving the fovea in patients with NVAMD including polypoidal choroidal vasculopathy (PCV)

Exclusion Criteria

* SFH in the study eye due to causes other than NVAMD
* Media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging
* Substantial loss of VA due to condition other than AMD
* Limited visual potential from substantial atrophy or fibrosis in fovea
* Poor visual potential with known permanent reduction in visual acuity prior to SFH

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No